Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the ...

Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...